Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Incannex Healthcare Inc. (IXHL) vs SCYNEXIS, Inc. (SCYX)

Incannex Healthcare Inc. and SCYNEXIS, Inc. are both Drug Manufacturers Specialty & Generic companies. SCYNEXIS, Inc. is the larger, with a market value of $45.0M against $40.7M — 1.1× the size. Incannex Healthcare Inc. has the higher net margin (0.00% vs −49.7%) and the lower return on invested capital (−2,022.1% vs −110.7%). Across the 16 metrics below, SCYNEXIS, Inc. leads on 9 and Incannex Healthcare Inc. on 7.

Valuation

Metric IXHL SCYX Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 26.27 2.52 2.25
P/B 0.54 0.78 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA 1.18 n/m 12.29
EV/Sales (19.01) 1.15 2.56
Earnings yield (514.59%) (47.61%) (2.99%)
Free cash flow yield (43.26%) (25.67%) 0.00%

Profitability

Metric IXHL SCYX Drug Manufacturers Specialty & Generic median
Gross margin (0.10%) 100.00% 53.94%
Operating margin 0.00% (109.90%) 0.00%
Net margin 0.00% (49.74%) 0.00%
Free cash flow margin 0.00% (64.67%) 0.00%
Return on equity (117.17%) (18.38%) (0.40%)
Return on assets (100.36%) (15.09%) (3.32%)
Return on invested capital (2,022.08%) (110.72%) 0.00%

Growth

Metric IXHL SCYX Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — 682.47% 10.01%
EPS growth (last fiscal year) (17.39%) 61.36% —
Revenue growth, 5-year CAGR (29.64%) 179.40% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IXHL SCYX Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.00 0.05
Current ratio 41.56 9.65 2.31
Net debt to EBITDA 0.64 2.54 0.85

Dividend

Metric IXHL SCYX Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric IXHL SCYX Drug Manufacturers Specialty & Generic median
Market cap 40.66m 44.98m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack